Navin Fluorine looks like that nerdy IIT topper who suddenly started partying—revenues zoomed 38.5% YoY this quarter, profits leaped 129% YoY, and the stock is chilling at a 69x P/E like it’s on some luxury vacation. But behind the glow, GST penalties of ₹38 crore, CEO resignations, and capex bills of ₹2200 crore are queuing up faster than Swiggy orders during IPL finals.
2. Introduction
Welcome to the story of Navin Fluorine International Ltd (NFIL)—a company that literally deals in gases but somehow manages to leave investors breathless.
Born in 1967, a proud offspring of the Padmanabh Mafatlal group, NFIL has grown from refrigerant gases to specialty chemicals, contract manufacturing, and now—fancy acronyms like HFOs and CDMO—all designed to impress analysts who secretly just want to know: “Boss, kitna margin hai?”
The company’s current price: a cool ₹4,791, market cap north of ₹24,500 crore. The PE? A nose-bleed 69x—yes, that’s double the industry average. If valuation bubbles could talk, they’d scream, “Fluorine se zyada hawa mein hai yeh.”
But don’t get distracted by the stock price. Look at the product mix:
High Performance Products (HPP): Refrigerant gases and fancy fluorides. (46% revenue)
Specialty Chemicals: Used in everything from pharma to agro. (41%)
CDMO: Custom manufacturing for global pharma giants. (13%)
Throw in a couple of multi-million-dollar Honeywell contracts and a European API deal, and you’ve got a cocktail that tastes strong—until you see the debt creeping to ₹1,466 crore and promoters slowly reducing stake (27.1% now, down from 29.4%).
So the real question: Is NFIL a fluorine-fueled Ferrari or just a Maruti 800 with neon lights?
3. Business Model – WTF Do They Even Do?
Think of Navin Fluorine as that one cousin who somehow gets invited to every wedding—because they bring something essential nobody else can.
Refrigerants: Their OG business. Earlier, HCFC-22 (R-22) gas was their hero, but since the world decided ozone depletion is not sexy, R-22 is on death row (phase-out by 2030). NFIL quickly pivoted to R-32 and other environment-friendly gases.
Specialty Fluorochemicals: The ‘designer wear’ of the chemical world. Used in pharma, agro, abrasives, and even glass and ceramics. Think Gucci but in molecules.
CDMO/CRAMS: Big pharma outsourcing chemical reactions to Dewas plant while NFIL earns fat fees. Basically, the BPO of chemistry.
High Performance Products (HPP): Where the big bucks are—especially after bagging $410 mn Honeywell contract for high-performance fluorochemicals.
Their facilities? Surat (main hub), Dewas (CDMO), and upcoming Dahej (₹450 crore HF capacity project + other capex bombs). R&D? DSIR-approved and boosted by Manchester Organics acquisition. Fancy, right?
Basically, NFIL is trying to balance between “old school gas supplier” and “future-ready specialty partner.” Or as we say in desi homes: ek haath se shaadi ka ladoo, doosre haath se gym ka protein shake.
4. Financials Overview
Here’s the juicy Q1FY25 comparison:
Metric
Latest Qtr (Q1FY25)
YoY Qtr (Q1FY24)
Prev Qtr (Q4FY25)
YoY %
QoQ %
Revenue
₹725 Cr
₹524 Cr
₹701 Cr
38.5%
3.4%
EBITDA
₹207 Cr
₹100 Cr
₹179 Cr
107%
15.6%
PAT
₹117 Cr
₹51 Cr
₹95 Cr
129%
23.2%
EPS (₹)
23.6
10.3
19.1
129%
23.5%
Commentary:
YoY growth looks like NFIL just found steroids—129% PAT growth is no joke.
EBITDA margins hit 29%, recovering from earlier lows.
Annualized EPS = ₹23.6 × 4 = ₹94.4 → P/E = 4791 ÷ 94.4 ≈ 50.7x. Screener shows 69x based on TTM, but real-time P/E is still Himalayan.
Question for readers: Would you pay 50x earnings for a company selling gases, or is this the financial equivalent of paying ₹500 for roadside momos?
5. Valuation Discussion – Fair Value Range Only
Let’s play valuation maths (don’t worry, I’ll keep it less boring than your CA prep):
Method 1: P/E
Industry PE = ~33. NFIL (growth premium) → reasonable range 35x–45x. EPS FY25E (annualized) = ~₹94. Fair Value Range = ₹3,290 – ₹4,230.
Method 2: EV/EBITDA
EV = ₹25,977 Cr. EBITDA FY25E (annualized from Q1) = 207 × 4 = 828 Cr. Current EV/EBITDA = 31.3x (vs peers 18–22x). Fair EV range → 20–25x → Value = ₹16,560–₹20,700 Cr. Equity Value ≈ ₹15,000–₹19,000 Cr → Per Share ≈ ₹2,930–₹3,720.
Method 3: DCF (simplified)
Assume 15% CAGR revenue growth, margins stable at 25%, discount rate 11%, terminal growth 4%. DCF spits out ~₹3,400–₹4,100.
Final Fair Value Range:₹2,900 – ₹4,200. (Current CMP ₹4,791 is already at the high end.)
⚠️ Disclaimer: This fair value range is for educational purposes only and is not investment advice.
